See more : Exasol AG (EXL.DE) Income Statement Analysis – Financial Results
Complete financial analysis of PELL Bio-Med Technology Co. Ltd. (6949.TW) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of PELL Bio-Med Technology Co. Ltd., a leading company in the Biotechnology industry within the Healthcare sector.
- International Precious Minerals Group, Inc. (IPMG) Income Statement Analysis – Financial Results
- Websolute S.p.A. (WEB.MI) Income Statement Analysis – Financial Results
- Genesis Photonics Inc. (3383.TW) Income Statement Analysis – Financial Results
- Newron Pharmaceuticals S.p.A. (NWPHF) Income Statement Analysis – Financial Results
- Mercury General Corporation (MCY) Income Statement Analysis – Financial Results
PELL Bio-Med Technology Co. Ltd. (6949.TW)
Industry: Biotechnology
Sector: Healthcare
About PELL Bio-Med Technology Co. Ltd.
PELL Bio-Med Technology Co., Ltd., a biomedical company, engages in the development of cell culture technologies and techniques for therapeutic applications. Its commercial products include good tissue practice laboratory infrastructure, adipose-derived stem cells (ADSC) for regenerative medicine, and CIK and DC-CIK against cancers. The company also develops medicines for various types of cancers, cell immunotherapy, and stem cell regenerative therapy technologies. In addition, it engages in the research and development of chimeric antigen receptor T cell (CAR-T), CAR-NK and CAR-?dT, and gene-modified ADSC. Further, the company develops products for B-NHL, ovarian cancer, multiple myeloma, and thyroid cancer indications. The company was founded in 2017 and is based in Taipei, Taiwan.
| Metric | 2023 | 2022 | 2021 |
|---|---|---|---|
| Revenue | 18.03M | 17.16M | 13.98M |
| Cost of Revenue | 44.17M | 59.45M | 48.51M |
| Gross Profit | -26.14M | -42.30M | -34.53M |
| Gross Profit Ratio | -144.96% | -246.53% | -247.05% |
| Research & Development | 239.61M | 142.36M | 136.71M |
| General & Administrative | 124.66M | 71.78M | 39.70M |
| Selling & Marketing | 20.84M | 10.46M | 15.08M |
| SG&A | 145.49M | 51.45M | 24.72M |
| Other Expenses | 0.00 | 3.93M | 8.27M |
| Operating Expenses | 385.11M | 193.81M | 161.43M |
| Cost & Expenses | 429.28M | 253.27M | 209.94M |
| Interest Income | 7.63M | 2.27M | 240.00K |
| Interest Expense | 2.56M | 1.36M | 1.52M |
| Depreciation & Amortization | 45.61M | 31.04M | 30.16M |
| EBITDA | -353.18M | -198.87M | -157.30M |
| EBITDA Ratio | -1,958.51% | -1,195.25% | -1,186.25% |
| Operating Income | -411.25M | -236.11M | -195.96M |
| Operating Income Ratio | -2,280.52% | -1,376.17% | -1,402.03% |
| Total Other Income/Expenses | 10.01M | 4.84M | 6.99M |
| Income Before Tax | -401.24M | -231.27M | -188.97M |
| Income Before Tax Ratio | -2,225.02% | -1,347.98% | -1,352.03% |
| Income Tax Expense | 2.00K | -1.14M | -14.00K |
| Net Income | -398.76M | -230.13M | -188.96M |
| Net Income Ratio | -2,211.26% | -1,341.32% | -1,351.93% |
| EPS | -8.62 | -5.87 | -5.68 |
| EPS Diluted | -8.62 | -5.87 | -5.68 |
| Weighted Avg Shares Out | 46.26M | 39.22M | 33.28M |
| Weighted Avg Shares Out (Dil) | 46.26M | 39.22M | 33.28M |
Source: https://incomestatements.info
Category: Stock Reports